Patents by Inventor Erik Remaut
Erik Remaut has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10385351Abstract: Lactococcus lactis strains with improved preservation characteristics, and improved acid and bile salt tolerance are disclosed. More specifically, a L. lactis strain having a heterologous trehalose-6-phosphate synthase gene and/or a trehalose-6-phosphate phosphatase gene, results in an accumulation of trehalose in the cytoplasm and/or in the cytoplasmic membrane. A L. lactis strain, having an internal trehalose concentration of at least 10 mg per gram cells (w/w) is disclosed.Type: GrantFiled: September 5, 2017Date of Patent: August 20, 2019Assignee: INTREXON ACTOBIOTICS NVInventors: Erik Remaut, Dirk Iserentant
-
Publication number: 20180016587Abstract: Lactococcus lactis strains with improved preservation characteristics, and improved acid and bile salt tolerance are disclosed. More specifically, a L. lactis strain having a heterologous trehalose-6-phosphate synthase gene and/or a trehalose-6-phosphate phosphatase gene, results in an accumulation of trehalose in the cytoplasm and/or in the cytoplasmic membrane. A L. lactis strain, having an internal trehalose concentration of at least 10 mg per gram cells (w/w) is disclosed.Type: ApplicationFiled: September 5, 2017Publication date: January 18, 2018Applicant: INTREXON ACTOBIOTICS NVInventors: Erik REMAUT, Dirk ISERENTANT
-
Patent number: 9790510Abstract: Lactococcus lactis strains with improved preservation characteristics, and improved acid and bile salt tolerance are disclosed. More specifically, a L. lactis strain having a heterologous trehalose-6-phosphate synthase gene and/or a trehalose-6-phosphate phosphatase gene, results in an accumulation of trehalose in the cytoplasm and/or in the cytoplasmic membrane. A L. lactis strain, having an internal trehalose concentration of at least 10 mg per gram cells (w/w) is disclosed.Type: GrantFiled: November 6, 2015Date of Patent: October 17, 2017Assignee: INTREXON ACTOBIOTICS NVInventors: Erik Remaut, Dirk Iserentant
-
Publication number: 20160076044Abstract: Lactococcus lactis strains with improved preservation characteristics, and improved acid and bile salt tolerance are disclosed. More specifically, a L. lactis strain having a heterologous trehalose-6-phosphate synthase gene and/or a trehalose-6-phosphate phosphatase gene, results in an accumulation of trehalose in the cytoplasm and/or in the cytoplasmic membrane. A L. lactis strain, having an internal trehalose concentration of at least 10 mg per gram cells (w/w) is disclosed.Type: ApplicationFiled: November 6, 2015Publication date: March 17, 2016Inventors: Erik Remaut, Dirk Iserentant
-
Patent number: 9200249Abstract: Lactococcus lactis strains with improved preservation characteristics, and improved acid and bile salt tolerance are disclosed. More specifically, a L. lactis strain having a heterologous trehalose-6-phosphate synthase gene and/or a trehalose-6-phosphate phosphatase gene, results in an accumulation of trehalose in the cytoplasm and/or in the cytoplasmic membrane. A L. lactis strain, having an internal trehalose concentration of at least 10 mg per gram cells (w/w) is disclosed.Type: GrantFiled: August 18, 2005Date of Patent: December 1, 2015Assignee: ACTOGENIX N.V.Inventors: Erik Remaut, Dirk Iserentant
-
Publication number: 20070258965Abstract: Lactococcus lactis strains with improved preservation characteristics, and improved acid and bile salt tolerance are disclosed. More specifically, a L. lactis strain having a heterologous trehalose-6-phosphate synthase gene and/or a trehalose-6-phosphate phosphatase gene, results in an accumulation of trehalose in the cytoplasm and/or in the cytoplasmic membrane. A L. lactis strain, having an internal trehalose concentration of at least 10 mg per gram cells (w/w) is disclosed.Type: ApplicationFiled: August 18, 2005Publication date: November 8, 2007Inventors: Erik Remaut, Dirk Iserentant
-
Publication number: 20070122427Abstract: The present invention relates to a microorganism, preferably a bacterial strain, preferably a non-pathogenic strain, preferably a non-invasive strain, preferably a food grade strain, preferably a gram-positive bacterial strain, delivering a trefoil peptide in vivo. Preferably said trefoil peptide is TFF1. The present invention further relates to a method for the delivery of trefoil peptide to the gastro-intestinal tract comprising the administration of such a bacterial strain. The present invention also relates to a pharmaceutical composition comprising a trefoil peptide delivering bacterium as well as methods of treatment of acute gastro-intestinal inflammatory diseases comprising administration of said transformed bacterial strains, particularly for treating acute colitis, including but not limited to acute flare-ups of Crohn's disease and ulcerative colitis in humans, as well as for treating gastro-intestinal disorders of a similar nature in other animal species.Type: ApplicationFiled: January 18, 2007Publication date: May 31, 2007Inventors: Wolfgang Hans, Lothar Steidler, Erik Remaut
-
Publication number: 20070110723Abstract: The present invention relates to a microorganism, preferably a bacterial strain, preferably a non-pathogenic strain, preferably a non-invasive strain, preferably a food grade strain, preferably a gram-positive bacterial strain, delivering a trefoil peptide in vivo. Preferably said trefoil peptide is TFF1. The present invention further relates to a method for the delivery of trefoil peptide to the gastro-intestinal tract comprising the administration of such a bacterial strain. The present invention also relates to a pharmaceutical composition comprising a trefoil peptide delivering bacterium as well as methods of treatment of acute gastro-intestinal inflammatory diseases comprising administration of said transformed bacterial strains, particularly for treating acute colitis, including but not limited to acute flare-ups of Crohn's disease and ulcerative colitis in humans, as well as for treating gastro-intestinal disorders of a similar nature in other animal species.Type: ApplicationFiled: January 18, 2007Publication date: May 17, 2007Inventors: Wolfgang Hans, Lothar Steidler, Erik Remaut
-
Publication number: 20050276788Abstract: The invention relates to a recombinant Lactobacillus strain, with limited growth and viability in the environment. More particularly, it relates to a recombinant Lactobacillus that can only survive in a medium, where well-defined medium compounds, preferably thymidine or thymine, are present. A preferred embodiment is a Lactobacillus that may only survive in a host organism, where the medium compounds are present, but cannot survive outside the host organism in absence of the medium compounds. Moreover, the Lactobacillus strain can be transformed with prophylactic and/or therapeutic molecules and can, as such, be used to treat diseases such as, but not limited to, inflammatory bowel diseases.Type: ApplicationFiled: May 12, 2005Publication date: December 15, 2005Applicants: Vlaams Interuniversitair Instituut Voor Biotechnologie VZW, Universiteit GentInventors: Lothar Steidler, Pieter Rottiers, Erik Remaut
-
Publication number: 20030202991Abstract: Biologically active polypeptides and/or antigens are delivered by administering to a subject a non-invasive or non-pathogenic bacterium which expresses one or more antigens or polypeptides. The non-invasive or non-pathogenic bacterium can be included in delivery systems or pharmaceutical formulations.Type: ApplicationFiled: January 22, 2003Publication date: October 30, 2003Inventors: Lothar Steidler, Erik Remaut, Jeremy Mark Wells, Richard William Falla Le Page
-
Patent number: 6605286Abstract: Biologically active polypeptides and/or antigens are delivered by administering to a subject a non-invasive or non-pathogenic bacterium which expresses one or more antigens or polypeptides. The non-invasive or non-pathogenic bacterium can be included in delivery systems or pharmaceutical formulations.Type: GrantFiled: April 16, 1998Date of Patent: August 12, 2003Assignees: Vlaams Interuniversitair Instituut voor Biotechnologie, Microbial Technics LimitedInventors: Lothar Steidler, Erik Remaut, Jeremy Mark Wells, Richard William Falla Le Page
-
Publication number: 20010006642Abstract: Methods of delivering biologically active polypeptides and/or antigens by administering to a subject a non-invasive or non-pathogenic bacterium which expresses the one or more antigens or polypeptides. Also, nucleic acids, delivery systems, pharmaceutical formulations comprising such delivery systems and methods of making same.Type: ApplicationFiled: April 16, 1998Publication date: July 5, 2001Inventors: LOTHAR STEIDLER, ERIK REMAUT, JEREMY MARK WELLS, RICHARD WILLIAM FALLA LE PAGE
-
Patent number: 6190662Abstract: Methods for obtaining surface expression of a desired protein or polypeptide in Gram-positive host organisms are provided. In addition, vectors useful in such methods as well as Gram-positive host organisms transformed with such vectors are disclosed.Type: GrantFiled: March 6, 1998Date of Patent: February 20, 2001Assignee: Vlaams Interuniversitair Instituut voor Biotechnologie (VIB) vzwInventors: Lothar Steidler, Erik Remaut, Jeremy Mark Wells
-
Patent number: 4874702Abstract: Improved vectors and methods for expressing cloned genes of prokaryotic or eukaryotic origin and methods of making such vectors are disclosed, the improved vectors comprising promoters and operators from .lambda. phages and preferably do not include an active cro gene or an active N gene, the vectors having at least one endonuclease recognition site for cloning desired genes less than about 300 base pairs from the promoters and operators and being useful, as are methods utilizing the vectors, in producing a wide variety of prokaryotic, eukaryotic and viral polypeptides, hormones, enzymes, antigens, proteins and amino acids.Type: GrantFiled: October 20, 1986Date of Patent: October 17, 1989Assignee: Biogen, Inc.Inventors: Walter C. Fiers, Rene Erik Remaut